Roivant Sciences Ltd. (ROIV)

合理估值

HealthcareBiotechnologyUnited Kingdom

基本面

价格

$36.39

市值

$26.42B

Yahoo Finance TradingView 新闻官网

第一部分 · 这家公司值多少

概览

Roivant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines and technologies. Its clinical product candidates include IMVT-1402, a fully human monoclonal antibody targeting FcRn in development across several IgG-mediated autoimmune indications; mosliciguat, an inhaled sGC activator in development for pulmonary hypertension associated with interstitial lung disease; neonatal fragment crystallizable receptor for the treatment of graves' disease, difficult-to-treat rheumatoid arthritis, sjögren's disease, myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, and cutaneous lupus erythematosus indications; batoclimab, a fully human monoclonal antibody for the treatment of thyroid eye disease; and brepocitinib, a potent small molecule inhibitor of TYK2 and JAK1 in development for the treatment of dermatomyositis, non-infectious uveitis, cutaneous sarcoidosis, and other immune-mediated diseases. The company's lead program consists of mosliciguat, an inhaled sGC activator for the treatment of pulmonary hypertension associated with interstitial lung disease and other cardiopulmonary diseases. In addition, the company offers delivery platforms comprising a lipid nanoparticle (LNP) platform and a ligand conjugate platform. Roivant Sciences Ltd. was founded in 2014 and is based in London, United Kingdom.

No editorial profile for this company yet

Direct competitors

Who this company fights with for the same customers

No editorial profile for this company yet

No competitor list for this company yet.

资产负债表与流动性

营收

$8M

最近12个月（截至2026/6/30）

净利润

$-266M

最近12个月（截至2026/6/30）

自由现金流

$-759M

股东权益合计

$4.53B

负债合计

$416M

流动比率

16.72

利息覆盖率

债务/EBITDA

每股收益

营收与净利润

自由现金流

收入构成

历史财务表

利润率变化

债务变化

债务负担有多重

增长一览表

增长 — 营业收入

公允价值估算

无营收阶段合理估值

公允价值

$32.07

当前价格

$36.39

安全边际

-13.5%

公允价值区间

$20.84 - $43.29

所用估值方法之间的离散区间，并非经过统计校准的置信区间。

估算方法

分析师目标价:$48.08

现金流折现法（DCF）:不适用于此类公司

市盈率法（P/E）:不适用于此类公司

格雷厄姆成长公式:不适用于此类公司

盈利能力价值（EPV）:不适用于此类公司

合理市净率（P/B）:不适用于此类公司

股息折现模型（戈登模型）:不适用于此类公司

P/FFO（运营资金）:不适用于此类公司

周期中段收益:不适用于此类公司

市销率法（P/S）:$0.04

分析师共识:强力买入 (17B / 2H / 0S)

最近财报超预期:+22.62%

估值指标

市盈率（P/E）

ROE

-6.6%

市净率（P/B）

6.24

P/FCF

毛利率

ROIC

-9.4%

盈利能力雷达图

价值创造（经济护城河）

ROIC

-9.4%

WACC

11.2%

ROIC − WACC

-20.6 pp

ROIC 低于资本成本：公司每投入一美元都在毁灭价值。

基本面分析标准

通过（7）

EPS shows upward trend
Price CAGR 23.92%
Debt/Equity ratio
Current Ratio
Low reliance on intangibles
Analyst Consensus 89% Buy
Share Dilution -22.5%

未通过（11）

ROIC -9.4%
P/B Ratio 6.24
Operating Margin -7914.8%
Positive Free Cash Flow
Return on Tangible Assets
DCF valuation (Unknown)
ROE -6.1%
Revenue Growth 5Y -19.1%
Earnings Surprise avg -2.3%
Net Margin Trend -3535.0% vs -2111.8%
Piotroski F-Score 1/9

不可用（9）

Gross Margin NaN%
P/FCF NaN
Dividend Payout NaN%
CapEx intensity
Interest Coverage
Debt/EBITDA
Price below Graham Number
PEG Ratio (need PE > 0 and growth > 0)
Earnings Quality (OCF/Net Income)

Piotroski F-评分

1/9

存在严重财务隐患

score

criteria

盈利质量

低质量：需深入审查会计处理

股权稀释

-22.5%

正在回购股份，对股东友好

机构持股

该公司暂无机构申报数据。

公司治理

管理团队

姓名	职位	年龄
Mr. Matthew Gline	CEO & Director	41
Dr. Eric Venker M.D., Pharm.D.	President & CEO of Immunovant	38
Dr. Mayukh Sukhatme M.D.	President, Chief Investment Officer & Director	49
Dr. Frank M. Torti M.B.A., M.D.	President & Vant Chair	46
Mr. Richard Pulik	Chief Financial Officer	45
Ms. Jennifer Humes	Chief Accounting Officer	44
Mr. Ian Rosenblum	Chief Information Officer	-
Mr. Sam Kaplan	General Counsel	-
Ms. Kelly Graff	Head of People	-
Mr. Alex Gasner	Executive Vice President of Roivant Health	-

审计风险

董事会风险

薪酬风险

股东权利风险

第二部分 · 价格与买入时机

这一部分不判断公司是否值得拥有：它帮助你在基本面说服你之后，选择何时买入。包含：技术分析、潜力、历史回撤、Gamma 敞口。

文件

年度报告（10-K）
对公司业务、财务业绩和风险的年度概述。
提交日期：2026-05-20
查看文件
季度报告（10-Q）
最近三个月财务表现的最新情况。
提交日期：2026-08-06
查看文件
临时报告（8-K）
关于重大事件（如管理层变动或重要公告）的通知。
提交日期：2026-09-18
查看文件

via SEC EDGAR

损益历史

via SEC EDGAR

Latest News

Recent headlines for ROIV, sourced from Markets Gazette.

8/6/2026POSITIVE
Roivant Expects FDA to Approve First Major Drug
Roivant Sciences Ltd. is anticipating FDA approval for its novel drug targeting a severe skin condition, with a market launch projected for September. CEO Matt Gline expressed optimism about the drug's potential. This development represents a significant milestone for Roivant, potentially unlocking a new revenue stream and validating its research and development pipeline. Investors will be closely watching the official FDA decision, as approval could lead to substantial growth and market share gains in the dermatology sector.

via Markets Gazette